AOA
0.003
50%
BOC
0.575
-50%
BUY
0.003
50%
TR2
0.34
-44.3%
ENL
0.033
43.5%
BLZ
0.002
-33.3%
ALM
0.007
40%
1AD
0.003
-25%
FBR
0.004
33.3%
C7A
0.003
-25%
AAU
0.01
25%
CTN
0.003
-25%
AUR
0.02
25%
RLC
0.003
-25%
MTM
0.855
24.8%
M2M
0.013
-23.5%
LM1
0.185
23.3%
IS3
0.018
-21.7%
SPQ
0.011
22.2%
EPM
0.015
-21.1%
PHX
0.14
21.7%
NFM
0.02
-20%
NHE
0.045
21.6%
OEL
0.004
-20%
PLC
0.006
20%
FMR
0.275
-16.7%
SHN
0.02
17.6%
KOB
0.06
-16.7%
AS2
0.014
16.7%
DY6
0.115
-14.8%
SIO
0.14
16.7%
MGU
0.006
-14.3%
ATC
0.029
16%
WLD
0.012
-14.3%
RLF
0.074
15.6%
ZMM
0.006
-14.3%
IMI
0.015
15.4%
HWK
0.025
-13.8%
PTX
0.062
14.8%
NVQ
0.02
-13%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts